A trial of RVT-103 for the treatment Alzheimer's disease and Lewy-body dementia.
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2017
At a glance
- Drugs Donepezil/glycopyrrolate (Primary)
- Indications Alzheimer's disease; Dementia
- Focus Adverse reactions; Proof of concept
- 13 Jun 2017 Results published in an Axovant Sciences Media Release
- 13 Jun 2017 According to an Axovant Sciences media release, the company is planning a RVT-104 proof of concept study (see profile 285954) based on data from this trial. This trial measured subject nausea in 48 healthy, elderly subjects.
- 09 Jan 2017 According to an Axovant Sciences media release, the first portion of the study has been competed and second portion of the study has begun. Results from the study are expected in the first half of 2017.